Effect of Donor Chose on the Outcomes of GVHD Prophylaxis Underwent the Combined Treatment of ATG/PTCy for Haplo-HSCT

Inclusion Criteria

• •1\. Acute myeloid leukemia was diagnosed according to the 2016ELN criteria with any of the following:
• •1. ELN prognostic stratification high-risk group (see Appendix for criteria)
• •2. Non-remission (NR) AML: including primary refractory AML and NR patients after relapse.
• •2\. Patients must have a suitable hematopoietic stem-cell donor.
• •1. Patients had to have a qualified haploidentical young male (≤30 years old) or female with a history of pregnancy;
• •2. Related donors had to be related donors matched 5/10-7/10 for HLA-A, -B, -C, -DQB1 and -DRB1 3. All the enrolled patients received a unified GVHD prevention regimen based on ATG and PTCy